Showing 4171-4180 of 5771 results for "".
- Nicox Partners With Laboratorios Grin to Bring Zerviate to Mexicohttps://modernod.com/news/nicox-partners-with-laboratorios-grin-to-bring-zerviate-to-mexico/2479169/Nicox SA announced the signature of an exclusive license agreement with Laboratorios Grin, a wholly-owned subsidiary of Lupin Limited, for the registration and commercialization of Zerviate (cetirizine ophthalmic solution) 0.24% in Mexico for the treatment of ocular itching associated with allerg
- Novartis’ Sandoz Unit Confirms Late-Stage Clinical Development Plans for Proposed Biosimilar Aflibercepthttps://modernod.com/news/novartis-sandoz-unit-confirms-late-stage-clinical-development-plans-for-proposed-biosimilar-aflibercept/2479166/Sandoz, a division of Novartis, announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical phase 3 confirmatory efficacy and safety study, shortly.1 Aflibercept (
- Nicox’s Licensee Bausch + Lomb Launches Vyzulta in Taiwan and Receives Approval in Qatarhttps://modernod.com/news/nicoxs-licensee-bausch-lomb-launches-vyzulta-in-taiwan-and-receives-approval-in-qatar/2479163/Nicox SA announced that its exclusive global licensee Bausch + Lomb has launched Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% in Taiwan. Regulatory approval in Taiwan was obtained in March 2020. Vyzulta has also recently received approval in Qatar. In addition to Taiwan, Vyzul
- Tarsus Pharmaceuticals Presents Results of Atlas Study Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-presents-results-of-atlas-study-demonstrating-the-functional-and-psychosocial-impact-of-demodex-blepharitis/2479161/Tarsus Pharmaceuticals announced data from its Demodex blepharitis clinical program presented at the virtual Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. Tarsus’ lead product candidate, TP-03, is a topical ophthalmic formulation of lotilaner, a well-characteriz
- Lineage Cell: OpRegen Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With GAhttps://modernod.com/news/lineage-cell-opregen-clinical-data-continues-to-demonstrate-improvements-in-patients-with-dry-amd-with-ga/2479160/Lineage Cell Therapeutics announced that updated interim results from its ongoing, 24-patient phase 1/2a clinical study of its lead product candidate, OpRegen, were reported at the 2021 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2021). OpRegen is an investigational
- Unity Biotechnology Presents Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseaseshttps://modernod.com/news/unity-biotechnology-presents-data-demonstrating-improvement-in-retinal-vasculature-and-function-in-preclinical-models-of-diabetic-retinopathy-eye-diseases/2479156/Unity Biotechnology announced preclinical data demonstrating that UBX1325, a novel senolytic small molecule inhibitor of Bcl-xL, improves retinal vasculature and is differentiated from anti-VEGF agents in preclinical models. Researchers show that inhibition of retinal Bcl-xL by UBX1325 selectivel
- jCyte Identifies Predictive Biomarker for jCell Therapy in Largest Phase 3 Study for Retinitis Pigmentosahttps://modernod.com/news/jcyte-identifies-predictive-biomarker-for-jcell-therapy-in-largest-phase-3-study-for-retinitis-pigmentosa/2479157/jCyte announced presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, identifying a predictive biomarker for the upcoming phase 3 study for jCell therapy in retinitis pigmentosa. A detailed analysis by the Cleveland Clinic Cole Eye Institute
- Ophtec Introduces Precizon Presbyopic Toric IOLhttps://modernod.com/news/ophtec-introduces-precizon-presbyopic-toric-iol/2479159/Ophtec announced the introduction of the Precizon Presbyopic Toric IOL, a spin-off of the Precizon Toric and Precizon Presbyopic. The IOL offers patients the qualities of both models, according to a company news release. The toric is unique because of its TCT (Transitional Conic Toric<
- Mallinckrodt Presents Data Evaluating Acthar Gel for the Treatment of Severe Keratitis at ARVOhttps://modernod.com/news/mallinckrodt-presents-data-evaluating-acthar-gel-for-the-treatment-of-severe-keratitis-at-arvo/2479153/Mallinckrodt announced data from its phase 4, multicenter, open-label study to assess the efficacy and safety of Acthar Gel (repository corticotropin injection) in adult patients with treatment-resistant, severe noninfectious keratitis, a disease which involves painful
- Novartis: Phase 3 Beovu Data Show Potential for Fluid Resolution in More DME Patients With Fewer Injections Versus Aflibercepthttps://modernod.com/news/novartis-phase-3-beovu-data-show-potential-for-fluid-resolution-in-more-dme-patients-with-fewer-injections-versus-aflibercept/2479150/Novartis announced positive 1-year results of the phase III KESTREL and KITE studies, evaluating the efficacy and safety of Beovu (brolucizumab-dbll) 6 mg in diabetic macular edema (DME). Both studies met their primary endpoints of noninferiority in change in best corrected visual acuity (